Indivior PLC (LON:INDV – Get Free Report) shares fell 17% during mid-day trading on Thursday . The company traded as low as GBX 548.71 ($6.93) and last traded at GBX 720.60 ($9.10). 2,904,792 shares changed hands during trading, an increase of 294% from the average session volume of 737,710 shares. The stock had previously closed at GBX 868 ($10.97).
Analyst Ratings Changes
Separately, Jefferies Financial Group restated a “buy” rating and issued a GBX 1,800 ($22.74) price objective on shares of Indivior in a research report on Tuesday, December 17th.
View Our Latest Stock Analysis on Indivior
Indivior Stock Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- How to Short a Stock in 5 Easy Steps
- DuPont’s Electronics Spinoff: The Start of Something Big
- Transportation Stocks Investing
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- What is the Dogs of the Dow Strategy? Overview and Examples
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.